Get started
Author

Volkmar Mueller

Observed names: Mueller Volkmar, Mueller, Volkmar
OpenAlex ID: A5125532406
Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2– LA/mBC): Primary analysis of the phase III persevERA BC trial.
2026 · Nicholas C. Turner, Komal L. Jhaveri, et al. · Journal of Clinical Oncology · 5
Tucatinib (TUC) combined with trastuzumab and pertuzumab (HP) as first-line (1L) maintenance therapy for HER2+ metastatic breast cancer (MBC): An in-depth safety analysis of HER2CLIMB-05.
2026 · Veronique C. Dieras, Giuseppe Curigliano, et al. · Journal of Clinical Oncology · 1
When do we need to take action? Cut-off values for the hamburg inventory for measuring quality of life in oncological patients (HELP-6)
2026 · Theresa Schrage, Mirja Görlach, et al. · Journal of Patient-Reported Outcomes
PDF
Additional file 1 of When do we need to take action? Cut-off values for the hamburg inventory for measuring quality of life in oncological patients (HELP-6)
2026 · Theresa Schrage, Mirja Görlach, et al. · Figshare
8th International consensus guidelines for the management of advanced breast cancer (ABC8 guidelines)
2026 · Fatima Cardoso, Joana Mourato Ribeiro, et al. · The Breast
Clinical Relevance of Post-Treatment Circulating Tumor DNA Detection in Early Breast Cancer Using a Tissue-Free Epigenomic Assay: A 2-Year Landmark Analysis
2026 · Thomas W. P. Friedl, Peter A. Fasching, et al. · JCO Precision Oncology
Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer
2026 · Veronique Dieras, Giuseppe Curigliano, et al. · Targeted Oncology
PDF
Interception of molecular relapse in breast cancer: The SURVIVE HERoes study (NCT06643585).
2026 · Wolfgang Janni, Thomas W. P. Friedl, et al. · Journal of Clinical Oncology
The SURVIVE study: Re-evaluating follow-up in early breast cancer.
2026 · Sophia T. Huesmann, Thomas W. P. Friedl, et al. · Journal of Clinical Oncology
Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.
2026 · Erika P. Hamilton, Giuseppe Curigliano, et al. · Journal of Clinical Oncology
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024
2024 · Thill, Marc, Janni, Wolfgang, et al. · RWTH Publications (RWTH Aachen)
Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in Healthcare
2023 · Mueller, Volkmar, Fasching, Peter A., et al. · RWTH Publications (RWTH Aachen)
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer : Update 2023
2023 · Park-Simon, Tjoung-Won, Mueller, Volkmar, et al. · RWTH Publications (RWTH Aachen)
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021
2021 · Thill, Marc, Friedrich, Michael, et al. · Kölner Universitäts PublikationsServer (Universität zu Köln)
Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - An analysis of the GeparSepto trial
2020 · Fasching, Peter A., Denkert, Carsten, et al. · RWTH Publications (RWTH Aachen)
Works count: 25
Citation count: 6
H-index: 1
I10-index:
Year
Topic
Type